> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# 10x Genomics Lifts 2026 Sales Outlook To $625 Million–$635 Million As Quarterly Loss Narrows
- URL: https://www.bullished.co/10x-genomics-lifts-2026-sales-outlook-to-625-million-635-million-as-quarterly-loss-narrows-aacc857d/
- Published: 2026-11-06T15:25:53.000Z
- Updated: 2026-11-06T15:25:53.000Z
- Description: Consumables sales increased while instrument revenue fell, and lower inventory markdowns helped improve gross margin.
- Author: Matteo Parrino
- Tags: Earnings, TXG, Industry: Healthcare

[10x Genomics](https://www.bullished.co/tag/txg/), which makes instruments, consumables and software for single-cell and tissue research, [raised its 2026](https://www.prnewswire.com/news-releases/10x-genomics-reports-third-quarter-2026-financial-results-302931240.html?ref=bullished.co) revenue outlook Thursday to [$625 million–$635 million](https://www.sec.gov/Archives/edgar/data/0001770787/000162828026071025/txg-20261105.htm?ref=bullished.co), from $610 million–$630 million, according to its earnings release accompanying an SEC filing. Third-quarter sales rose 1%, but lower costs and a changed product mix produced a larger improvement in its losses.

## Consumables Grow, Instrument Sales Fall

Quarterly revenue reached [$150.7 million](https://www.sec.gov/Archives/edgar/data/0001770787/000162828026071025/txg-20261105xexx991.htm?ref=bullished.co), compared with $149.0 million a year earlier. TXG shares rose about 2% to $59.30 in Friday trading.

Consumables brought in $134.327 million, versus $127.892 million a year earlier. Within that business, products used to map biology within tissue generated $41.188 million, compared with $35.373 million; single-cell consumables generated $93.139 million, versus $92.519 million.

Instrument revenue moved the other way, falling to $6.858 million from $11.999 million. Services revenue increased to $9.025 million from $8.128 million.

The annual outlook carries an important distinction: management expects growth of 4%–6% when non-recurring patent-settlement license and royalty revenue is excluded from both 2026 and 2025\. For the first nine months, total revenue was $452.546 million versus $476.793 million, while products and services revenue increased to $449.200 million from $430.999 million.

## Lower Markdowns Improve Gross Margin

The company retained [75% of sales](https://www.sec.gov/Archives/edgar/data/0001770787/000162828026071025/txg-20261105xexx991.htm?ref=bullished.co) after product and service costs, up from 67% a year earlier. Management attributed the improvement mainly to smaller inventory markdowns and the mix of products sold.

Operating expenses fell 3% to [$129.0 million](https://www.prnewswire.com/news-releases/10x-genomics-reports-third-quarter-2026-financial-results-302931240.html?ref=bullished.co) from $132.5 million. Reduced personnel and laboratory-equipment spending outweighed an increase in litigation costs.

The operating loss narrowed to $16.1 million from $32.2 million. The net loss also shrank, to $19.4 million from $27.5 million, with the per-share loss declining to $0.15 from $0.22.

## Atera Ships, Sentira Adds AI Analysis

The business serves academic and government researchers as well as biopharmaceutical and biotechnology institutions. Its Chromium platform examines individual cells; Visium and Xenium help researchers locate molecules within tissue.

10x began worldwide commercial shipments of Atera and introduced Sentira, a cloud-based tool for analyzing biological datasets. Sentira uses NVIDIA computing to process spatial data and Anthropic’s Claude for AI analysis of single-cell data.

Serge Saxonov, co-founder and CEO of 10x Genomics, connected broader business results to consumables: “We were also encouraged with the results across our broader business, driven by continued strength in consumables.”

10x ended September with $575.7 million in cash, cash equivalents and marketable securities, alongside a smaller quarterly operating loss.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — 10x Genomics, Inc. (TXG)](https://www.sec.gov/Archives/edgar/data/0001770787/000162828026071025/txg-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit txg-20261105xexx991.htm — 10x Genomics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001770787/000162828026071025/txg-20261105xexx991.htm?ref=bullished.co) — SEC EDGAR
- [10x Genomics: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/10x-genomics-q3-earnings-snapshot/616-2c0f2009-4969-4ae7-a4db-b7dbed8a842a?ref=bullished.co) — Associated Press
- [10x Genomics Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/10x-genomics-reports-third-quarter-2026-financial-results-302931240.html?ref=bullished.co) — prnewswire.com

### More on 10x Genomics

- [10x Genomics Says Factory And Install Capacity, Not Orders, Will Cap Atera At About 50 A Quarter](https://www.bullished.co/10x-genomics-says-factory-and-install-capacity-not-orders-will-cap-atera-at-about-50-a-867f1cf7/)
- [10x Genomics Seats A Stanford Immunologist And Glaukos's Operating Chief, With A New Audit Chair](https://www.bullished.co/10x-genomics-seats-a-stanford-immunologist-and-glaukoss-operating-chief-with-a-new-audit-876cd012/)
- [ARK And Cathie Wood Report 5.22% Stake In 10x Genomics, 6,272,998 Shares, In 13G/A](https://www.bullished.co/ark-and-cathie-wood-report-5-22-stake-in-10x-genomics-6-272-998-shares-in-13g-a-59c899ea/)

[All 10x Genomics (TXG) coverage →](https://www.bullished.co/tag/txg/)